Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Present with chronic plaque psoriasis based on a confirmed diagnosis of chronic plaque psoriasis for at least 6 months prior to first dose of study drug~* At least 10% Body Surface Area (BSA) of psoriasis at screening and at first dose of study drug~* Static Physician Global Assessment (sPGA) score of at least 3 and Psoriasis Area and Severity Index (PASI) score of at least 12 at screening and at first dose of study drug~* Candidate for phototherapy and/or systemic therapy~* Men must agree to use a reliable method of birth control or remain abstinent during the study~* Women must agree to use reliable birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment~Exclusion Criteria:~* Pustular, erythrodermic, and/or guttate forms of psoriasis~* History of drug-induced psoriasis~* Prior use of etanercept~* Clinically significant flare of psoriasis during the 12 weeks prior to randomization~* Concurrent or recent use of any biologic agent~* Received non-biologic systemic psoriasis therapy or phototherapy (including psoralens and ultraviolet A \[PUVA\], ultraviolet B \[UVB\]) within the previous 4 weeks; or had topical psoriasis treatment within the previous 2 weeks prior to randomization~* Cannot avoid excessive sun exposure or use of tanning booths for at least 4 weeks prior to randomization and during the study~* Have participated in any study with interleukin 17 (IL-17) antagonists, including ixekizumab~* Serious disorder or illness other than plaque psoriasis~* Serious infection within the last 3 months~* Breastfeeding or nursing (lactating) women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 80 mg ixekizumab Dosing Regimen 1 (Type: EXPERIMENTAL): Administered by two 80 mg subcutaneous (SC) injections at Week 0, then one 80 mg SC injection per Dosing Regimen 1 until Week 12. At Week 12, ixekizumab responders are re-randomized to placebo, Dosing Regimen 2 or Dosing Regimen 3. Ixekizumab non-responders are assigned to Dosing Regimen 2.
- 80 mg ixekizumab Dosing Regimen 2 (Type: EXPERIMENTAL): Administered by two 80 mg SC injections at Week 0, then one 80 mg SC injection per Dosing Regimen 2 until Week 12. At Week 12, ixekizumab responders are re-randomized to placebo, Dosing Regimen 2 or Dosing Regimen 3. Ixekizumab non-responders are assigned to Dosing Regimen 2.
- 80 mg ixekizumab Dosing Regimen 3 (Type: EXPERIMENTAL): Dosing Regimen 3 is not used until Week 12. At Week 12, ixekizumab responders re-randomized to this arm will receive Dosing Regimen 3.
- 50 mg etanercept (Type: ACTIVE_COMPARATOR): Administered by one 50 mg SC injection twice weekly starting at Week 0 up to Week 12. At Week 12, etanercept responders are assigned to placebo, and nonresponders to Dosing Regimen 2.
- Placebo for ixekizumab (Type: PLACEBO_COMPARATOR): Placebo for ixekizumab administered by two SC injections at Week 0, then one SC injection per Dosing Regimen 1 until Week 12. At Week 12, placebo responders are assigned to placebo, and nonresponders to Dosing Regimen 2. Placebo for etanercept administered by one SC injection twice weekly starting at Week 0 up to Week 12 was used to blind etanercept injections for Dosing Regimen 1, Dosing Regimen 2, and Placebo Comparator groups.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete